PubRank
Search
About
Brian A Crowe
Author PubWeight™ 13.19
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Lancet Infect Dis
2013
3.46
2
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.
Vaccine
2007
1.35
3
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
PLoS One
2010
1.15
4
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.
PLoS One
2011
1.07
5
A new approach to a Lyme disease vaccine.
Clin Infect Dis
2011
0.96
6
Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
Vaccine
2009
0.95
7
Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
J Virol
2009
0.94
8
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
PLoS One
2010
0.90
9
Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.
PLoS One
2011
0.85
10
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.
Hum Vaccin Immunother
2013
0.81
11
Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
PLoS One
2013
0.78
12
A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Vaccine
2012
0.75